Bucking weak investor interest in the life sciences, Paris-based Sofinnova--a longtime player in biotech venture circles--has put together a $312 million fund that will be entirely dedicated to the life sciences.
The Cambridge, MA-based biotech's CEO tells FierceBiotech that the company has topped up its accounts with $13 million in fresh venture cash from its consortium of A-list backers. Read more >>
Instead of taking assets to proof-of-concept in a fast march through the clinic and then striking deals for their programs, as originally planned, Flexion's top execs have seized on the success of their clinical-stage osteoarthritis drugs and plan to stay focused on their pipeline--pursuing late-stage work, perhaps all the way through Phase III.
Even a casual observer of the biotech industry would know that Cambridge, MA, has seen a booming biotech sector fueled with a steady stream of venture deals. And in a year when venture deals and dollars have been considerably constricted overall, the Cambridge hub has continued to hum with VC activity.
Pearl Therapeutics has grabbed a hefty $65 million venture round, enough to bankroll the launch of a key late-stage COPD drug program that--one way or another--will prove transformational for the biotech.
Just a few months after MEI Pharma ($MEIP) in-licensed a lead cancer program from S*Bio in Singapore, the drug developer put together $27.5 million in private financing to fuel an effort to push the HDAC inhibitor through a key mid-stage study. A pair of venture groups--Vivo Ventures and New Leaf Venture Partners--joined RA Capital Management and Three Arch Opportunity Fund in the raise.
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
The Kirkland, WA-based venture firm is among the casualties of a sinking venture industry, and its eventual demise means one less source of fresh capital for startups in biotech and other sectors.
Menlo Park, CA-based Longitude Capital has rounded up $385 million for a new life sciences investment fund, exceeding its initial goal of $325 million. That money will be reserved for biotechs and device companies that have shown promise in mid-stage development or nearing commercialization, targeting a three- to five-year time horizon on payoffs.
Affimed Therapeutics has scored 15.5 million euros ($20.1 million) more in venture cash for clinical trials of its drugs that hit two targets with one antibody to kill cancer.